NovaXS (Needle-free pistol for injections)

2022: Go to Market Device

In early April 2022, NovaXS Biotech announced the launch of a needle-free injector, which can make treatments that traditionally require daily self-medication less painful. NovaXS comes with a cloud-based platform that collects patient information for doctors, such as injection time, frequency, dose volume, and drug temperature.

For mass product shipments, NovaXS Biotech attracted investments from the following partners: Courtyard Ventures (focused on startups at the University of California, Berkeley), MHub Impact Fund (an innovation center from Chicago), medical equipment manufacturer Baxter and Edward Elmhurst Health (an integrated health care system in Illinois). Chinese venture capital firm NewGen VC also joined the $1.5 million funding round. The investment company AiBasis, led by Baidu co-founder Lei Min, and Boston-based Taihill Venture expressed great interest in the project. After closing of a sowing round of NovaX Biotech plans to work on safety and stability of the products, to submit the application for obtaining permission to the Food and Drug Administration (FDA) and to gather the main team of managers for advance of the product on the market.

Market Entry NovaXS

The injection gun NovaXS, which patients can conveniently hold in their hand, can inject biologics subcutaneously and intramuscularly for 0.3 seconds with fluid pressure. The startup has already found the first two uses - in vitro fertilization and drug delivery in Duchenne muscular dystrophy (MDD). Initially, NovaX Biotech targets gene therapy and IVF, as these areas have the greatest potential to gain large market share. The company also plans to work on other diseases that require injections at home, such as diabetes and growth hormone disorders in children.^[1]

Notes